Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Despite guideline recommendations and available evidence, implementation of treatment in
heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses …

Background Guidelines recommend early initiation of multiple guideline-directed medical
therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and …

Heart failure (HF) is common and associated with a poor prognosis, despite advances in
treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co …

Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life
and a major burden for the healthcare system. The number of patients that progress to an …

Background Previous reports suggest that risk factors, management, and outcomes of acute
heart failure (AHF) may differ by sex, but they rarely extended analysis to low-and middle …

Major changes have occurred in these last years in heart failure (HF) management.
Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis …

Guideline‐directed medical therapy (GDMT) has the potential to reduce the risks of mortality
and hospitalisation in patients with heart failure (HF) with reduced ejection fraction (HFrEF) …

Background Patients with heart failure (HF) are often cared for by non-cardiologists. The
implications are unknown. Methods In a nationwide HF cohort with reduced ejection fraction …